# Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

> **NCT05099445** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 48 (actual)

## Conditions studied

- Renal Impairment
- Hemodialysis

## Interventions

- **DRUG:** INCB000928

## Key facts

- **NCT ID:** NCT05099445
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-14
- **Primary completion:** 2023-02-19
- **Final completion:** 2023-02-27
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05099445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05099445, "Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05099445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*